In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Rite Aid Corporation
(NYSE:RAD), Infosys Limited (NYSE:INFY), Morningstar, Inc.
(NASDAQ:MORN), Western Digital Corporation (NASDAQ:WDC), Hemispherx
BioPharma, Inc. (NYSE:HEB), and Chanticleer Holdings, Inc.
(NASDAQ:BURG), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified
analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
RAD DOWNLOAD: http://Capital-Review.com/register/?so=RAD
INFY DOWNLOAD: http://Capital-Review.com/register/?so=INFY MORN
DOWNLOAD: http://Capital-Review.com/register/?so=MORN WDC DOWNLOAD:
http://Capital-Review.com/register/?so=WDC HEB DOWNLOAD:
http://Capital-Review.com/register/?so=HEB BURG DOWNLOAD:
http://Capital-Review.com/register/?so=BURG
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Rite Aid
Corporation (NYSE:RAD), Infosys Limited (NYSE:INFY), Morningstar,
Inc. (NASDAQ:MORN), Western Digital Corporation (NASDAQ:WDC),
Hemispherx BioPharma, Inc. (NYSE:HEB), and Chanticleer Holdings,
Inc. (NASDAQ:BURG) on a fundamental level and outlines the overall
demand for their products and services in addition to an in-depth
review of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently
released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
RITE AID CORPORATION (RAD) REPORT OVERVIEW
Rite Aid's Recent Financial Performance
For the three months ended February 28th, 2019
vs February 28th, 2018, Rite Aid reported revenue of $5,379.65MM vs
$5,394.26MM (down 0.27%) and analysts estimated basic earnings per
share -$0.26 vs $0.73. For the twelve months ended February 28th,
2019 vs February 28th, 2018, Rite Aid reported revenue of
$21,639.56MM vs $21,528.97MM (up 0.51%) and analysts estimated
basic earnings per share -$0.40 vs $0.90. Analysts expect earnings
to be released on June 26th, 2019. The report will be for the
fiscal period ending May 31st, 2019. The reported EPS for the same
quarter last year was -$0.01.
To read the full Rite Aid Corporation (RAD) report, download it
here:
http://Capital-Review.com/register/?so=RAD
-----------------------------------------
INFOSYS LIMITED (INFY) REPORT OVERVIEW
Infosys' Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Infosys reported revenue of $2,987.00MM vs
$2,755.00MM (up 8.42%) and analysts estimated basic earnings per
share $0.12 vs $0.17 (down 29.41%). For the twelve months ended
March 31st, 2018 vs March 31st, 2017, Infosys reported revenue of
$10,939.00MM vs $10,208.00MM (up 7.16%) and analysts estimated
basic earnings per share $0.55 vs $0.47 (up 17.02%). Analysts
expect earnings to be released on July 12th, 2019. The report will
be for the fiscal period ending June 30th, 2019. Reported EPS for
the same quarter last year was $0.14. The estimated EPS forecast
for the next fiscal year is $0.61 and is expected to report on
April 10th, 2020.
To read the full Infosys Limited (INFY) report, download it
here:
http://Capital-Review.com/register/?so=INFY
-----------------------------------------
MORNINGSTAR, INC. (MORN) REPORT OVERVIEW
Morningstar's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Morningstar reported revenue of $262.70MM
vs $243.10MM (up 8.06%) and analysts estimated basic earnings per
share $1.00 vs $0.92 (up 8.70%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Morningstar reported
revenue of $1,019.90MM vs $911.70MM (up 11.87%) and analysts
estimated basic earnings per share $4.30 vs $3.21 (up 33.96%).
Analysts expect earnings to be released on April 24th, 2019. The
report will be for the fiscal period ending March 31st, 2019.
To read the full Morningstar, Inc. (MORN) report, download it
here:
http://Capital-Review.com/register/?so=MORN
-----------------------------------------
WESTERN DIGITAL CORPORATION (WDC) REPORT
OVERVIEW
Western Digital's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Western Digital reported revenue of
$4,233.00MM vs $5,336.00MM (down 20.67%) and basic earnings per
share -$1.68 vs -$2.78. For the twelve months ended June 30th, 2018
vs June 30th, 2017, Western Digital reported revenue of
$20,647.00MM vs $19,093.00MM (up 8.14%) and analysts estimated
basic earnings per share $2.27 vs $1.38 (up 64.49%). Analysts
expect earnings to be released on April 29th, 2019. The report will
be for the fiscal period ending March 31st, 2019. The reported EPS
for the same quarter last year was $3.36. The estimated EPS
forecast for the next fiscal year is $4.04 and is expected to
report on July 25th, 2019.
To read the full Western Digital Corporation (WDC) report,
download it here:
http://Capital-Review.com/register/?so=WDC
-----------------------------------------
HEMISPHERX BIOPHARMA, INC. (HEB) REPORT
OVERVIEW
Hemispherx BioPharma's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Hemispherx BioPharma reported revenue of
$0.24MM vs $0.05MM (up 380.00%) and analysts estimated basic
earnings per share -$0.03 vs -$0.06. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Hemispherx BioPharma
reported revenue of $0.37MM vs $0.44MM (down 16.02%) and analysts
estimated basic earnings per share -$0.22 vs -$0.29. Analysts
expect earnings to be released on May 15th, 2019. The report will
be for the fiscal period ending March 31st, 2019.
To read the full Hemispherx BioPharma, Inc. (HEB) report,
download it here:
http://Capital-Review.com/register/?so=HEB
-----------------------------------------
CHANTICLEER HOLDINGS, INC. (BURG) REPORT
OVERVIEW
Chanticleer's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Chanticleer reported revenue of $10.12MM vs
$10.08MM (up 0.37%) and analysts estimated basic earnings per share
-$0.58 vs -$0.43. For the twelve months ended December 31st, 2018
vs December 31st, 2017, Chanticleer reported revenue of $40.61MM vs
$41.43MM (down 1.98%) and analysts estimated basic earnings per
share -$1.98 vs -$2.73. Analysts expect earnings to be released on
May 13th, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was -$0.30. The estimated EPS forecast for the next fiscal year is
-$0.96 and is expected to report on April 6th, 2020.
To read the full Chanticleer Holdings, Inc. (BURG) report,
download it here:
http://Capital-Review.com/register/?so=BURG
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Apr 2023 to Apr 2024